Now I'll produce the final consolidated review.

## Summary

ProteinVista introduces a compute-efficient 3D CNN that voxelizes full-atom protein structures at 1.0Å resolution, is pre-trained on ~500K AlphaFold-2 structures (via contrastive alignment with ESM-2), and fine-tuned on protein-ligand interaction tasks. The key technical contributions are: (1) an adaptive-boxing strategy that minimizes empty voxel volume, enabling a 123M-parameter 3D CNN to train in 48 hours on 4 A100 GPUs—roughly 1% of the GPU-hours required for ESM-2₆₅₀M; (2) extensive 3D rotation augmentation during pre-training that makes fine-tuning robust to orientation; and (3) an informative ablation study isolating the effect of each design choice. The paper convincingly demonstrates that a full-atom 3D CNN can be computationally practical and complementary to sequence-based models.

## Strengths

- **Compute efficiency is rigorously demonstrated.** ProteinVista pre-trains in ~192 GPU-hours (48 h × 4 A100 GPUs) versus ESM-2₆₅₀M's ~21,504 GPU-hours. At inference, it processes 1,000 proteins in 20 seconds on a single A100—over 20× faster than ESM-2₆₅₀M (426 s). Figure 3 cleanly visualizes the parameter count, FLOPs, speed, and storage trade-offs. This is a practically meaningful advantage that directly counters the conventional wisdom that full-atom 3D CNNs are prohibitively expensive.

- **The ablation study on IC₅₀ prediction (Section 4.2) is informative and non-obvious.** It tests the number of inference views, the pre-training objective, and voxel resolution on a single benchmark, quantifying each factor's relative impact. The finding that disabling rotation augmentation during fine-tuning has essentially no effect (-0.1%), while a single inference view costs 6.4% R², is a specific result that will help practitioners.

- **The analysis of when structure helps (Section 4.1) is a genuine strength.** Stratifying by sequence identity, TM-score, and AlphaFold pLDDT confidence reveals that ProteinVista adds the most value on high-confidence structures and on proteins with high sequence/structure similarity to the training set—while the ESM-ProteinVista ensemble is robust across all regimes. This provides practical guidance for users.

- **Honest reporting of the GO annotation weakness (Section 3.4).** ProteinVista (Fmax=0.57) underperforms ESM-2₆₅₀M (0.62) on homology-driven function prediction, and the paper explicitly states that "structure encoders add limited value" for such tasks. This delineation of scope strengthens the paper's credibility.

## Weaknesses

### Major

- **The introduction (line 33) claims "ProteinVista surpasses current best methods" for transporter and enzyme substrate prediction, but the standalone model does not.** On TSP, ProteinVista alone (90.8%) is below SPOT (92.4%); on ESP, ProteinVista alone (91.8%) is below ProSmith-ESP (94.2%) and Fusion_ESP (94.2%). Only the ESM-enhanced ensemble with the optimized pipeline (ESM-ProteinVista_OP) beats these SOTA methods on both benchmarks. The abstract correctly limits its claim to "outperforms sequence transformers," but the introduction's broader phrasing is misleading and needs correction. The standalone model's contribution—competitive performance with far less compute—is still valuable, and the paper should present it as such without overclaiming.

- **No comparison against existing structure-aware methods.** The introduction motivates ProteinVista by arguing that residue-level graph networks (GearNet, ESM-GearNet, DeepFRI) "omit atom-level details," yet the experiments never compare against any of these methods. If the paper's core motivation is that full-atom 3D CNNs capture information missing from residue graphs, then the evaluation should test this directly. Without it, the experiments only show that structure helps over sequence (which is already known), not that *this particular structural representation* (full-atom voxel CNN) is better than *other structural representations* (residue-level graphs). This is the most consequential gap in the evaluation.

- **The contrastive pre-training dependency on ESM-2 is not acknowledged in the abstract or introduction.** The model is pre-trained with an InfoNCE loss that pulls its embeddings toward ESM-2 embeddings of the same protein (Section 2.3). While the paper describes this in the methodology, the high-level framing presents ProteinVista as independently outperforming sequence transformers without noting that it was explicitly trained to align with one. This concern is *partially* mitigated by the ablation showing that replacing contrastive alignment with Rosetta-score regression reduces R² by only 1.0% (Section 4.2), indicating the performance does not rely exclusively on ESM-2 alignment. Still, transparent disclosure in the abstract would be appropriate.

### Minor

- **No uncertainty quantification for any individual-model comparison.** Tables 1 and 2 report all metrics as point estimates without standard deviations or confidence intervals. For ESP, ProteinVista (91.8%) and ESM-2₆₅₀M (91.9%) differ by only 0.1 percentage points—essentially identical—but there is no way to assess whether this difference (or the 1.5-point TSP gap) is meaningful. The statistical tests reported (McNemar's, Wilcoxon) compare the *ensemble* against ESM-2, not ProteinVista alone against ESM-2. Reporting variance across multiple seeds or train/test splits would significantly strengthen the central comparisons.

### Trivial

None.

## Nice-to-Haves

- Adding a baseline with *randomly initialized* (no pre-training) ProteinVista would quantify the benefit of pre-training itself, beyond the architecture.
- Expanding the IC₅₀ benchmark to include a structure-aware drug-target interaction baseline (e.g., a binding-pocket-based or 3D GNN method) would contextualize the R²=0.69 result beyond the sequence-only comparisons.

## Removed Points

*These points were flagged during consolidation and are kept here for completeness but do not appear in the main review.*

- **Voxel density equation formatting (Section 2.1).** The critic noted a possible parser artifact or missing square term. Removed per hard rules: these are formatting/parser issues, not author errors.
- **FLOPs vs. runtime discrepancy (Section 4.3).** The critic requested more detailed explanation of the 10× speedup for 3× the FLOPs. Removed: the paper provides a reasonable explanation (better parallelizability of shallow 3D CNNs), and this does not threaten any core claim.
- **GPU architecture difference (H100 vs A100).** The critic noted that comparing GPU-hours across architectures is approximate. Removed: the qualitative conclusion of a large efficiency gain is robust even with architectural differences.
- **IC₅₀ ensemble drop.** The critic questioned why the ensemble performs worse than ProteinVista alone. This is a known observation that the paper explicitly discusses and explains; it is not a weakness.
- **Missing from-scratch training baseline.** Moved to Nice-to-Haves: the paper already compares two pre-training objectives, and the from-scratch experiment, while useful, is not standard for this type of pre-training paper.

## Novel Insights

The reviewer observation that the stratification by sequence identity (Section 4.1a) shows ProteinVista capturing the functional impact of individual amino acid substitutions better than sequence models in the high-identity bins is a finding that the paper itself does not fully articulate as a distinct result. Conversely, the absence of any structure-aware baseline means we cannot tell whether this behavior is unique to the voxel CNN or shared by any structure-based method, limiting the insight's scope.

## Suggestions

1. **Reframe the SOTA claims.** Clearly separate standalone ProteinVista results from the ESM-ProteinVista_OP ensemble results in the abstract and introduction. The standalone model's genuine contribution—competitive performance at a fraction of the compute—stands on its own.
2. **Add at least one structure-aware baseline.** Comparing against GearNet or ESM-GearNet on the same benchmarks would directly test the paper's stated motivation and substantially strengthen the contribution.
3. **Report variance.** Include results across multiple random seeds (or at minimum clarify the number of runs) for the individual-model comparisons that underpin the paper's main claims.
4. **Acknowledge the pre-training dependency.** Add a note in the abstract or introduction that the primary pre-training objective aligns with ESM-2 embeddings, while noting the ablation evidence that this is not the sole source of performance.

## Score and Decision

**Calibration anchors used:**

| Path | Avg Human Score | Round | Itemized | Comparison |
|---|---|---|---|---|
| ProteiNexus (iBAWiEjogY) | 3.67 | R1 | Yes | Weaker paper with data leakage and more severe missing-baseline concerns; my paper is stronger |
| Pre-training Sequence/Structure/Surface (BEH4mGo7zP) | 5.75 | R1 | Yes | Accepted paper with incremental gains; my paper has similar method quality but a harder overclaim issue |
| ProteinWorkshop (sTYuRVrdK3) | 6.25 | R1+R2 | Yes | Benchmark contribution with very high-favorability strengths; my paper is a method paper and weaker |
| Multimodal Distillation (O0dW800ukz) | 5.67 | R2 | Yes | Rejected with similar weakness profile (missing baselines, unclear motivation) but less severe overclaim |

**Score rationale:** My draft's most negative weakness items (favorability ≈ -1.7 for missing baselines and ESM-2 dependency) are substantially less damaging than ProteiNexus's worst (-4.14) but more notable than the accepted Pre-training paper's. They are comparable in magnitude to the Multimodal Distillation paper's negative items (-3.19 missing baselines), which was rejected at 5.67. The paper has real value—the compute efficiency demonstration, informative ablations, and honest GO reporting are genuine contributions. However, the introduction's overclaim about "surpassing current best methods" and the missing comparison against structure-aware methods are fixable but significant weaknesses that prevent the paper from making a clean case for its stated claims. A score of 5.0 reflects a borderline paper that has substantive contributions but requires major framing corrections and additional comparisons to fully substantiate its claims.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>